Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences of Niigata University, 1-754, Asahimachi-Dori, Niigata-city, 951-8122, Japan,
Hepatol Int. 2008 Sep;2(3):382-7. doi: 10.1007/s12072-008-9084-z. Epub 2008 Jul 25.
To study the changes in serum ferritin levels in lamivudine (LAM)-treated patients with chronic hepatitis and liver cirrhosis type B and determine whether successful treatment with LAM results in a reduction of serum ferritin levels.
Thirty patients with chronic hepatitis B virus (HBV) infection were followed prospectively during their treatment with LAM for 12 months. Serum HBV DNA, ferritin levels, and emergence of YMDD mutants were monitored. A case of severe liver cirrhosis with hepatic hemosiderosis that was treated successfully with LAM also is shown as a representative case.
Serum alanine aminotransferase and ferritin levels decreased significantly more in the patients treated with LAM without YMDD mutants (n = 23) than those with mutants (n = 7). Hepatic hemosiderosis along with serum iron markers improved greatly in the representative patient.
Successful treatment with LAM may reduce serum ferritin levels and improve hepatic siderosis in a subset of patients with chronic HBV infection.
研究拉米夫定（LAM）治疗慢性乙型肝炎和肝硬化患者血清铁蛋白水平的变化，确定 LAM 是否能成功降低血清铁蛋白水平。
前瞻性观察 30 例慢性乙型肝炎病毒（HBV）感染者，用 LAM 治疗 12 个月，监测血清 HBV DNA、铁蛋白水平及 YMDD 突变的出现。并以一例成功用 LAM 治疗的严重肝硬化伴肝血色素沉着症患者为例。
在无 YMDD 突变（n=23）的 LAM 治疗患者中，血清丙氨酸氨基转移酶和铁蛋白水平显著降低，而在有突变（n=7）的患者中则无显著变化。该代表患者的肝血色素沉着症和血清铁标志物明显改善。
在慢性 HBV 感染的部分患者中，LAM 的成功治疗可能降低血清铁蛋白水平并改善肝铁沉积。
